Do the omeprazole family compounds exert a protective effect against influenza-like illness?

BMC Infectious Diseases

Donatella Panatto³  Daniela Amicizia³  Stefania Rossi¹  Maria Luisa Cristina⁴  Sara Boccalini²  Cecilia Trucchi⁴  Francesca Casabona⁴  Piero Luigi Lai³  Roberto Gasparini³ 

[1] Department of Molecular and Developmental Medicine, Siena University, Siena, Italy;Department of Health Sciences, Florence University, Firenze, Italy;Inter-University Centre for Research on Influenza and other Transmitted Infections (CIRI-IT), Genoa, Italy;Department of Health Sciences, Genoa University, Genoa, Italy

关键词: Prevention;    Epidemiology;    Omeprazole family compounds;    Influenza-like illness (ILI);   

Others  :  1127686
DOI  :  10.1186/1471-2334-14-297

 received in 2013-03-11, accepted in 2014-05-28,  发布年份 2014

【 摘 要 】

Background

Infections by influenza viruses place a heavy burden on public health and economies worldwide. Although vaccines are the best weapons against influenza, antiviral drugs could offer an opportunity to alleviate the burden of influenza. Since omeprazole family compounds block the “proton pump”, we hypothesized that they could interfere with the mechanism of fusion of the virus envelope and endosomal membrane, thereby hindering the M2 proton pump mechanism of influenza viruses.

Methods

A matched case-control study was performed in 2010-2011 in Italy. Cases were subjects aged over 18 years with a diagnosis of Influenza-like Illness (ILI); 254 case-control pairs were recruited. A multivariable conditional logistic regression analysis was used to assess the association between the prevention of ILI and the administration of omeprazole family compounds. The interaction between omeprazole family compounds and influenza vaccination was also examined.

Results

After control for potential confounders, subjects treated with omeprazole family compounds displayed a lower risk of catching ILI (OR_adj = 0.29, 95% CI: 0.15-0.52). The risk of ILI in unvaccinated non-OFC users was about six times than that in vaccinated OFC users.

Conclusions

Although confirmation is necessary, these results suggest that omeprazole family compounds could be profitably used in the prevention of ILI.

【 授权许可】

   
2014 Gasparini et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]World Health Organization: State of the art of new vaccines: research and development. Geneva, Switzerland: World Health Organization Document Production Services; 2006. [Available at: http://www.path.org/vaccineresources/files/New_vaccines_rsch_dev.pdf webcite] Accessed on June 5, 2014
• [2]Center for Diseases Control (CDC): Seasonal Influenza-Associated Hospitalizations in the United States. [Available at: http://www.cdc.gov/flu/about/qa/hospital.htm webcite] Accessed on July 15, 2011
• [3]Lai PL, Panatto D, Ansaldi F, Canepa P, Amicizia D, Patria AG, Gasparini R: Burden of the 1999-2008 seasonal influenza epidemics in Italy: comparison with the H1N1v (A/California/07/09) pandemic. Hum Vaccin 2011, 7(Supp):217-225.
• [4]Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB: The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
• [5]Monto AS: Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 2006, 12:55-60.
• [6]Wang C, Takeuchi K, Pinto LH, Lamb RA: Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993, 67:5585-5594.
• [7]Ziegler T, Hemphill ML, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW, Regnery HL, Cox NJ: Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999, 180:935-939.
• [8]Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI: Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
• [9]World Health Organization Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Revised February 2010 Part I: Recommendations Pharmacological Management of Pandemic Influenza A (H1N1) 2009 Part I: Recommendations. [Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf webcite.] Accessed on July 15, 2011
• [10]Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y: Resistant A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
• [11]Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006, 50:1470-1479.
• [12]Ooi EE, Chew JS, Loh JP, Chua RC: In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006, 3:39. BioMed Central Full Text
• [13]Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA: Drugs in development for influenza. Drugs 2010, 70:1349-1362.
• [14]Ikematsu H, Kawai N: Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther 2011, 9:851-857.
• [15]Yamaya M, Shinya K, Hatachi Y, Kubo H, Asada M, Yasuda H, Nishimura H, Nagatomi R: Clarithromycin Inhibits Type A Seasonal Influenza Virus Infection in Human Airway Epithelial Cells. J Pharmacol Exp Ther 2010, 333:81-90.
• [16]DeVincenzo JP: The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir Ther 2012, 17:213-225.
• [17]Tsiodras S, Mooney JD, Hatzakis A: Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ 2007, 334:293-294.
• [18]Carraro G, Naso A, Montomoli E, Gasparini R, Camerini R, Panatto D, Tineo MC, De Giorgi L, Piccirella S, Khadang B, Ceracchi M, De Rosa A: Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine 2012, 30:1170-1180.
• [19]Stedman CAM, Barclay ML: Review article: comparison of pharmacokinetics acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000, 14:963-978.
• [20]Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, Nishimura H, Sasaki H: The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol 2005, 509:201-210.
• [21]Lamb RA, Zebedee SL, Richardson CD: Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
• [22]Schulz FK, Grimes DA: Case-control studies: research in reverse. Lancet 2002, 359:431-434.
• [23]Influenza-like illness case definition [Available at: http://www.acha.org/ILI_Project/ILI_case_definition_CDC.pdf webcite.] Accessed on September 3, 2011
• [24]Boivin G, Hardy I, Tellier G, Maziade J: Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000, 31:1166-1169.
• [25]INFLUNET – Italian Influenza Surveillance Network [Available at: http://www.salute.gov.it/portale/temi/p2_5.jsp?lingua=italiano&area=influenza&menu=sorveglianza webcite] Accessed on June 5, 2014
• [26]Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" Gazzetta Ufficiale n. 174 del 29 luglio 2003 - Supplemento Ordinario n. 123. [Available at: http://www.camera.it/parlam/leggi/deleghe/03196dl.htm webcite] Accessed on June 5, 2014
• [27]International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10] [Available at: http://www.who.int/classifications/icd/en/ webcite] Accessed on June 5, 2014
• [28]Victora CG, Huttly SR, Fuchs SC, Olinto MT: The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol 1997, 26:224-227.
• [29]Blot WJ, Day NE: Synergism and interaction: are they equivalent? Am J Epidemiol 1979, 110:99-100.
• [30]Saracci R: Interaction and synergism. Am J Epidemiol 1980, 112:465-466.
• [31]Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE: Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol 2011, 26:433-438.
• [32]Knol MJ, VanderWeele TJ: Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol 2012, 41:514-520.
• [33]de Jager DJ, de Mutsert R, Jager KJ, Zoccali C, Dekker FW: Reporting of interaction. Nephron Clin Pract 2011, 119:c158-c161.
• [34]Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A: Calculating measures of biological interaction. Eur J Epidemiol 2005, 20:575-579.
• [35]Chang KW, Lin SJ, Hsueh C, Kong MS: Menetrier’s disease associated with cytomegalovirus infection in a child. Acta Paediatr Taiwan 2000, 41:339-340.
• [36]Hong S, Pedersen PL: ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol Mol Biol Rev 2008, 72:590-641.
• [37]Pinto LH, Lamb RA: Influenza virus proton channels. Photochem Photobiol Sci 2006, 5:629-632.
• [38]Casasnovas JM, Springer TA: Pathway of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released. J Virol 1994, 68:5882-5889.
• [39]Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
• [40]van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG: Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006, 61:957-961.